SS-31

Name: SS-31
Brand: PeptideValidation.com
Availability: OutOfStock

SS-31 Recovery, Healing & Tissue Repair Peptides

SS-31 (Elamipretide) is a revolutionary, first-in-class mitochondria-targeted peptide designed to restore cellular energy production, eradicate oxidative stress at its source, and reverse age-related biological decay. By physically rehabilitating the inner mitochondrial membrane, it offers unprecedented clinical efficacy in reversing heart failure, protecting renal function, reversing cognitive decline, and accelerating holistic systemic recovery.

Access Certified Vendors View Testing Standards

View full details

Quick Facts

SS-31 (Elamipretide) is a revolutionary, first-in-class mitochondria-targeted peptide designed to restorecellular energy production, eradicate oxidative stress at its source, and reverse age-related biologicaldecay. By physically rehabilitating the inner mitochondrial membrane, it offers unprecedented clinicalefficacy in reversing heart failure, protecting renal function, reversing cognitive decline, and acceleratingholistic systemic recovery.

Generic Name

SS-31 (Elamipretide / Bendavia)

Drug Class

Szeto-Schiller Mitochondria-Targeted Peptide

Administration

Subcutaneous Injection

FDA Approval

Investigational (Fast Track for Mitochondrial Diseases)

Typical Maintenance Dose

2mg to 4mg

Starting Dose

2mg daily

Injection Sites

Abdomen, Thigh, Upper Arm

Treatment Duration

Cyclic administration (4-12 weeks) or long-term for chronic decay

Storage

Refrigerated (2°C - 8°C) once reconstituted

Prescription Required

Yes

Average Outcome

Massive restoration of physical energy, endurance, and cognitiveclarity

Best For

Chronic fatigue, neurodegeneration, cardiovascular repair, anti-aging

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational peptide that belongs to a class of compounds known as triple receptor agonists. It is designed to activate three key metabolic hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.Retatrutide is being studied in metabolic and obesity-related research because of its unique multi-receptor mechanism of action. Unlike traditional single-pathway compounds, Retatrutide targets multiple metabolic signaling pathways that researchers believe may influence appetite regulation, energy expenditure, glucose metabolism, and body weight.Developed by Eli Lilly and Company, Retatrutide has become one of the most widely discussed investigational peptides in metabolic research and is currently being evaluated in ongoing clinical studies. Retatrutide is a novel triple agonist peptide targeting the GLP-1, GIP, and glucagon receptors simultaneously.

Retatrutide (LY3437943) is a novel investigational peptide developed by Eli Lilly and Company. It is classified as a triple agonist, meaning it simultaneously activates three distinct hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-receptor engagement sets Retatrutide apart from every other metabolic research peptide currently in development or on the market.

As of 2023, Retatrutide has demonstrated unprecedented weight loss outcomes in Phase 2 clinical trials, with participants achieving a mean body weight reduction of up to 24.2% over 48 weeks — making it the most effective weight loss compound ever tested in a randomized controlled trial at the time of publication.

How Does Retatrutide Work?

Retatrutide works by binding to and activating three key metabolic hormone receptors in the body. Each receptor plays a distinct role in energy metabolism, appetite regulation, and glucose homeostasis. By engaging all three simultaneously, Retatrutide creates a synergistic effect that exceeds what any single or dual agonist can achieve.

Why Was Retatrutide Developed?

Retatrutide was developed to address the limitations of first and second generation metabolic peptides. While semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) demonstrated significant efficacy, researchers hypothesized that adding glucagon receptor activity could further enhance energy expenditure through thermogenesis and hepatic fat reduction.

What Receptors Does It Target?

GLP-1 Receptor — Controls insulin secretion, slows gastric emptying, and signals satiety to the brain
GIP Receptor — Enhances insulin sensitivity, augments GLP-1 effects, and modulates lipid metabolism
Glucagon Receptor — Increases energy expenditure via thermogenesis and reduces hepatic fat accumulation

How Is Retatrutide Different From Other Peptides?

Only peptide in development targeting GLP-1, GIP AND glucagon simultaneously
Highest weight loss outcomes ever recorded in a randomized controlled trial (24.2%)
Significant reduction in liver fat — addressing NAFLD and metabolic liver disease
Improvements in cardiometabolic markers including blood pressure and lipid profiles
Once-weekly subcutaneous injection with a favorable tolerability profile

💉 Receptor Target

GLP-1 Receptor

Stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and activates satiety pathways in the hypothalamus to reduce food intake.

⚡ Receptor Target

GIP Receptor

Enhances glucose-stimulated insulin secretion, improves insulin sensitivity in peripheral tissues, augments GLP-1 activity, and modulates lipid metabolism and adipose tissue function.

🔥 Receptor Target

Glucagon Receptor

Increases hepatic glucose production, stimulates thermogenesis and energy expenditure, promotes lipolysis, and directly reduces liver fat — a key differentiator from GLP-1/GIP dual agonists.

The simultaneous activation of all three receptors creates a synergistic metabolic effect that exceeds single-receptor targeting alone.

SS-31 Research Studies

Published clinical and preclinical research on SS-31.

Heart Failure Reversal

SS-31 Heart Failure Reversal

In preclinical and early clinical models of heart failure with reduced ejection fraction (HFrEF), SS-31 administration normalized mitochondrial architecture, profoundly increasing ATP availability and restoring myocardial contractility without placing additional oxygen demand on the heart.

Prevention of Acute Kidney Injury (AKI)

SS-31 Prevention of Acute Kidney Injury (AKI)

Clinical data has consistently demonstrated that treating subjects with SS-31 prior to ischemic renal insults entirely prevents the collapse of glomerular filtration rates and halts the long-term progression of renal fibrosis leading to chronic kidney disease.

Reduction of ROS Production

SS-31 Reduction of ROS Production

Unlike standard antioxidants that fail to penetrate the mitochondria, SS-31 concentrates 5,000-fold in the inner mitochondrial membrane, preventing the creation of excess reactive oxygen species by stabilizing the electron transport chain.

Retatrutide vs Other Peptides

How does Retatrutide compare to other leading research peptides?

Feature	Semaglutide	Tirzepatide	Liraglutide
Weekly Injection	Yes	Yes	Daily
Appetite Control	Excellent	Excellent	Moderate
Average Weight Loss	15-17%	20%+	6-8%
Dosing Frequency	Weekly	Weekly	Daily
Blood Sugar Support	Yes	Yes	Yes
Long-Term Data	Extensive	Growing	Established
Convenience	High	High	Moderate

Tirzepatide vs Semaglutide

Tirzepatide may produce greater weight loss due to its dual-agonist mechanism (GIP + GLP-1).
Semaglutide currently has longer-term weight management data available.
Both medications require physician supervision and dose titration.

Tirzepatide vs Liraglutide

Tirzepatide requires only weekly injections, whereas Liraglutide requires daily administration.
Tirzepatide produces vastly superior weight reduction (20%+ compared to Liraglutide's 6-8%).

PeptideValidation Testing & Validation

Every product undergoes rigorous multi-layer laboratory validation.

🔬

Medical History

History of cardiovascular disease, heart failure, or previous ischemic events.
Review of progressive cognitive decline, neurodegenerative symptoms, or severe chronic fatigue.
Assessment of renal function history and risk for acute kidney injury.

🔬

Laboratory Testing

Comprehensive Metabolic Panel (CMP) focusing on baseline kidney function (BUN/Creatinine, eGFR).
Cardiovascular markers: Lipid panels, hs-CRP, and BNP (Brain Natriuretic Peptide).
Advanced mitochondrial function panels or organic acids testing if available.
Echocardiogram (if utilizing for cardiac rehabilitation).

🔬

Monitoring During Treatment

MDT

Subjective tracking of physical energy levels, stamina, and exercise tolerance.
Cognitive assessments for improvements in memory, focus, and reduction of brain fog.
Follow-up cardiovascular and renal blood panels every 8-12 weeks to objectively measure metabolic repair.

Frequently Asked Questions

Everything you need to know about peptide testing, certification, and compliance.

How quickly does SS-31 work?

Because SS-31 directly addresses cellular energy production, many patients report a profound shift in
energy, mental clarity, and stamina within the first week of administration. For structural repair—such as
reversing cardiac hypertrophy or healing renal tissue—measurable clinical changes typically require
several months of consistent therapy.

Is SS-31 better than taking oral antioxidants like Vitamin C or CoQ10?

Yes, fundamentally. Standard oral antioxidants have extremely poor mitochondrial penetration and
attempt to "scavenge" damage after it has occurred. SS-31 actively targets the inner mitochondrial
membrane to fix the structural leak, preventing the damage from being created in the first place while
simultaneously ramping up energy production.

Can I combine SS-31 with NAD+ supplements?

Absolutely. Combining SS-31 with NAD+ precursors (like NMN or NR) is considered a "holy grail" of
anti-aging therapy. NAD+ provides the required metabolic fuel for the cell, while SS-31 ensures the
mitochondrial engine is perfectly repaired to utilize that fuel without breaking down.

Does SS-31 have any harsh side effects?

Because SS-31 operates on fundamental biological pathways to restore natural function rather than
forcing an artificial pharmacological response, it boasts an excellent safety profile. It does not cause
systemic immunosuppression or dangerous overstimulation.

Does it require refrigeration?

Yes. SS-31 is a highly sensitive tetrapeptide. Once the lyophilized powder is reconstituted with
bacteriostatic water, the vial must be stored in the refrigerator (between 2°C and 8°C) to prevent
degradation and maintain maximum potency.

Certification Standards

Certified Vendor Requirements

To qualify as a PeptideValidation.com Certified Vendor, companies must meet our rigorous multi-step testing and documentation standards. Certification is not bought — it is earned through independent verification.

🏆 Apply for Certification

To qualify, vendors must:

📦

Submit Batch Testing
Vendors must submit product samples for independent third-party lab testing before listing.
✅

Pass Purity Requirements
All products must meet minimum purity thresholds verified by HPLC analysis.
🔬

Verify Identity via LC-MS
Molecular identity of each compound confirmed through liquid chromatography-mass spectrometry.
📄

Maintain Full Documentation
COAs, batch records, and testing documentation must be publicly available on the vendor profile.
🔄

Undergo Quarterly Re-Testing
Certification requires mandatory re-testing every quarter to maintain active certified status.